Shepherding Therapeutic Cancer Vaccines through Clinical Development | Page 2

www.clinipace.com

Overview of Therapeutic Cancer Vaccines

The worldwide
market for
therapeutic
cancer vaccines
was $137 million
in 2010 and could
reach $2.9 billion
in 2014.

Therapeutic cancer vaccines hold great potential for patient benefit and
commercial profit. In the United States, it is estimated that more than 1.5
million new cancer cases will be diagnosed in 2011 (ACS, 2011). The worldwide
market for therapeutic cancer vaccines was $137 million in 2010 and could
reach $2.9 billion in 2014 (BCC Research, 2011). Yet the history of cancer
vaccine development is riddled with failures. Several vaccines have progressed
to phase 3 clinical trials only to fail to meet efficacy measures. In some cases,
the failures resulted in the demise of not only promising therapeutics but also
the companies developing them.
The only currently marketed therapeutic vaccine, Pr